Patent ID: 7108990

Claim:
A process for providing a pharmaceutical composition, comprising: (a) identifying a modulator of the binding of CCX CKR polypeptide to a chemokine comprising (i) contacting an isolated or recombinant CCX CKR polypeptide having the amino acid sequence as set forth in SEQ ID NO:2, or a fragment or variant thereof, and the chemokine in the presence of a test compound, and (ii) comparing the level of binding of the chemokine and the polypeptide in the presence of the test compound with the level of binding in the absence of the test compound, wherein the CCX CKR polypeptide, fragment or variant can bind the chemokine in the absence of test compound and the variant has at least 90% sequence identity to SEQ ID NO:2, the chemokine is selected from the group consisting of ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1γ (murine macrophage inflammatory protein 1γ) and vMIPII (viral macrophage inflammatory protein II), and a decrease in binding indicates that the test compound is an inhibitor of binding and an increase in binding indicates that the test compound is an enhancer of binding; and (b) formulating the modulator identified in (a) as a pharmaceutical composition.